2017
Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications
Wu B, Mottola G, Schaller M, Upchurch GR, Conte MS. Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. Molecular Aspects Of Medicine 2017, 58: 72-82. PMID: 28765077, PMCID: PMC5660644, DOI: 10.1016/j.mam.2017.07.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSpecialized pro-resolving lipid mediatorsVascular injuryLipid mediatorsVSMC migrationPro-resolving lipid mediatorsVascular smooth muscle cell activationSmooth muscle cell activationSpecialized lipid mediatorsAcute vascular injuryElaboration of cytokinesDisease-related eventsEndothelial cell disruptionMuscle cell activationImportant clinical contextsClearance of debrisMatrix protein depositionLeukocyte effluxBypass GraftingBypass surgeryBalloon angioplastyLeukocyte recruitmentAneurysm formationInflammatory signalsExperimental aneurysm formationLumen compromise
2007
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value In Health 2007, 10: 367-376. PMID: 17888101, DOI: 10.1111/j.1524-4733.2007.00190.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrostadienesAntineoplastic ProtocolsAromatase InhibitorsBreast NeoplasmsCost-Benefit AnalysisDrug Administration ScheduleFemaleForecastingHumansMarkov ChainsMiddle AgedNeoplasm Recurrence, LocalPostmenopauseQuality-Adjusted Life YearsSEER ProgramSelective Estrogen Receptor ModulatorsTamoxifenConceptsIntergroup Exemestane StudyDisease-free survivalDisease-related eventsTreatment strategiesEarly-stage breast cancer patientsEarly-stage breast cancerProlongs disease-free survivalCost-effective treatment strategyIncremental cost-effectiveness ratioYears of tamoxifenYears of therapyBreast cancer patientsSEER-Medicare dataBreast cancer statusLifetime medical care costsMedical care costsCost-effectiveness ratioTamoxifen therapyPostmenopausal womenRecurrence rateCancer careCancer patientsPatient transitionsAromatase inhibitorsBreast cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply